BC022687 Activators
BC022687 activators represent a chemical class designed to selectively augment the activity of the molecular target identified as BC022687. The initial phase in the development of these activators involves high-throughput screening (HTS), where a diverse chemical library is meticulously tested for compounds that can activate BC022687. This screening employs sophisticated assays that can precisely detect the activation of BC022687 through quantifiable signals, such as enhanced fluorescence or luminescence. These signals indicate the success of a compound in increasing the activity of BC022687, and compounds that stand out during this process are marked for further investigation. The secondary screening phase involves more refined assays tailored specifically to the BC022687 target. These assays confirm the primary HTS results and validate the compounds as true activators by demonstrating their specific interaction with BC022687 and their capacity to upregulate its activity.
Upon the successful identification of potential BC022687 activators, detailed studies are conducted to unravel the interaction between these compounds and BC022687. Structural determination techniques, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, are employed to discern the three-dimensional arrangement of these activators when bound to BC022687. Understanding the molecular structure of the activator-BC022687 complex is crucial for identifying the mechanism of activation and for the design of more effective activators. These studies can reveal the exact binding sites, the orientation of the compounds within these sites, and any structural changes in BC022687 that are associated with activation. In parallel, quantitative biophysical methods, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), provide essential data regarding the strength and kinetics of the interaction between BC022687 and its activators. These methods assess how strongly and quickly the activators bind to BC022687, which is critical for understanding their efficacy.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing cAMP breakdown, IBMX can indirectly increase PKA activity, which may lead to the phosphorylation and activation of "BC022687" within its relevant signaling cascades. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can result in altered phosphorylation states of proteins within signaling pathways, potentially leading to the activation of "BC022687" if it is regulated by PKC-mediated signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit several protein kinases. This inhibition can shift the balance of cellular signaling pathways, potentially leading to the activation of "BC022687" if it is involved in the pathways affected by these kinases. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P acts on G protein-coupled receptors to initiate signaling cascades that can lead to the activation of various intracellular proteins. If "BC022687" is influenced by GPCR-mediated signaling, S1P could indirectly enhance its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, potentially resulting in the activation of "BC022687" if it is part of or regulated by these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can disrupt downstream signaling pathways, which may include de-repression or activation of "BC022687" if it is part of the PI3K/Akt pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, U0126 can alter the signaling dynamics within the pathway, potentially leading to the activation of "BC022687" if it is regulated by ERK-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 can modulate cellular responses and potentially activate "BC022687" if it is influenced by the p38 MAPK signaling axis. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, which can activate various calcium-dependent proteins and pathways. If "BC022687" is activated by calcium signaling, A23187 could be an indirect activator of its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum inhibitor of protein kinases. Though it generally inhibits kinase activity, in some contexts, it can lead to the selective activation of signaling cascades that include "BC022687," particularly if feedback inhibition is removed. | ||||||